EXTON, PA — October 10, 2025 — Leads & Copy — Rheumatologists are eagerly anticipating the potential approval of brepocitinib, Priovant Therapeutics’ dual TYK2/JAK1 inhibitor, as a near-term advance for dermatomyositis (DM). According to Spherix Global Insights’ latest Market Dynamix™: Idiopathic Inflammatory Myopathies (US) service, physicians view brepocitinib as a leading pipeline candidate to deliver on the most urgent treatment goal in IIM: safe and effective steroid sparing.
The Phase 3 VALOR study, completed earlier this year, is designed to measure improvement using the Total Improvement Score (TIS) at one year, with steroid tapering measures built into the protocol. This resonates with rheumatologists who cite glucocorticoid dependence as a major barrier to long-term disease control. Brepocitinib’s once-daily oral administration and dual mechanism of action offer promise to shift this paradigm. Physicians project notable uptake following approval, with use concentrated among DM patients needing durable, steroid-sparing efficacy.
Spherix’s research highlights the unmet need across the Idiopathic Inflammatory Myopathy (IIM) spectrum, including clinically amyopathic DM (CADM), necrotizing myopathy (NM), anti-synthetase syndrome (ASyS), and inclusion body myositis (IBM), with IBM rated the most difficult to manage. These conditions are marked by delayed diagnosis, severe manifestations, and poor responses to existing regimens.
Physicians report barriers related to insurance approvals and access, reinforcing the importance of developing new agents and ensuring practical delivery and equitable patient access.
Spherix will monitor rheumatologists’ early experiences, adoption trends, and market dynamics through its Launch Dynamix™ service if brepocitinib is approved. The findings suggest brepocitinib may represent the first tangible advance in IIM in years, with potential to reshape care for DM. The broader IIM population remains in urgent need of innovation.
Market Dynamix™ analyzes markets anticipated to experience a paradigm shift, highlighting market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.
Launch Dynamix™ benchmarks newly launched products for the first eighteen months of commercial availability, with a quarterly deep dive into promotional activity, barriers to uptake, and patient types gravitating to the launch brand.
About Spherix Global Insights
Spherix is a market intelligence and advisory firm delivering commercial value to the global life sciences industry. Spherix experts provide an unbiased view of rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix’s market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.
Lynn Price, Rheumatology Franchise Head Spherix Global Insights 4848794284 lynn.price@spherixglobalinsights.com
Source: Spherix Global Insights
